2016 | |
---|---|
Criterium: | Position: |
Overall Score: | > 1000 |
Networking Rank (Reputation): | > 1000 |
2012 | |
Criterium: | Position: |
Overall Score: | 900-1000 |
Total Project Funding per Partner: | > 1000 |
Total Number of Projects: | 69 |
Total Project Funding: | > 1000 |
Networking Rank (Reputation): | > 1000 |
Networking Rank (Reputation): | > 1000 |
Partner Constancy: | 46 |
Project Leadership Index: | 75 |
Diversity Index: | 60 |
2011 | |
Criterium: | Position: |
Overall Score: | > 1000 |
Networking Rank (Reputation): | > 1000 |
2009 | |
Criterium: | Position: |
Overall Score: | > 1000 |
Networking Rank (Reputation): | > 1000 |
2007 | |
Criterium: | Position: |
Overall Score: | > 1000 |
Networking Rank (Reputation): | > 1000 |
Total number of projects: 5
As coordinator: 0
As participant: 5
Sole participant: 0
Coordinator / Participant Ratio: 0*
Total project funding [€]: | Projects [No]: | |||||
---|---|---|---|---|---|---|
Year: | coordinator* | participant* | per partner | as coordinator | as participant | |
2013 | 0 | 5.999.991 | 266.484 | 1 | ||
2012 | 0 | 10.712.424 | 905.769 | 2 | ||
2011 | 0 | 5.993.695 | 85.000 | 1 | ||
2010 | 0 | 3.000.000 | 0 | 1 |
Total number of partners: 68
Partner loyalty:
Frequent Partner: (> 2 projects): 0
Rare Partner: 68
Frequent / Rare Partner Ratio: 0
Start date | Project | acronym | role | funding | partners |
---|---|---|---|---|---|
2013-11-01 | Labeling of Enalapril from Neonates up to Adolescents | LENA | participant | 5.999.991 | 12 |
2012-11-01 | A phase I/IIa clinical trial in Duchenne muscular dystrophy using systemically delivered morpholino antisense oligomer to skip exon 53 | SKIP-NMD | participant | 5.512.424 | 10 |
2012-01-01 | European clinical study for the application of regenerative heart valves | ESPOIR | participant | 5.200.000 | 15 |
2011-02-01 | PanCare Childhood and Adolescent Cancer Survivor Care and Follow-up Studies | PanCareSurFup | participant | 5.993.695 | 17 |
2010-11-01 | Suicidality: Treatment Occurring in Paediatrics | STOP | participant | 3.000.000 | 19 |